Tenelia
(teneligliptin)ApprovedSmall molecule
Tanabe Pharma CorporationTeneligliptin is used to help control blood sugar levels in people with type 2 diabetes. It works by helping the pancreas release more insulin when blood sugar is high.[2] Tenelia is currently approved and in use across 4 indications[4].[1]
Tenelia is one of 94 small molecule programs targeting Type 2 Diabetes Mellitus. It is currently in Approved.
4
Indications
20
Total Trials
0
Active Trials
93
Competitors
Pipeline
Status by Indication[4][1]
Indication
Competition
Competitive Landscape
885 competitors in Type 2 Diabetes
#DrugCompanyPhaseTrials
1Tenelia
Tanabe Pharma CorporationApproved
Jardiance
Boehringer IngelheimPreclinical
NOVOLIN R
Novo NordiskPreclinical
Cecon
MMcGuff Pharmaceuticals, Inc.
Preclinical
Forxiga
AstraZenecaPreclinical
Lovaza
AstraZenecaPreclinical
Sulfonylureas
Eli LillyPreclinical
Acipimox
Boehringer IngelheimPreclinical
SGLT-2 Inhibitor
SSheffield Teaching Hospitals NHS Foundation Trust
Preclinical
GLP-1
RRigshospitalet, Denmark
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Type 2 Diabetes7 trials
Show 4 more trials
Empagliflozin3 trials
Type 2 Diabetes Mellitus2 trials
Left ventricular diastolic dysfunction1 trial
6 more indications
Metformin1 trial
Combination Therapy1 trial
Unspecified1 trial
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Tenelia drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for teneligliptin. EMBL-EBI & Wellcome Sanger Institute.
- [5]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Dipeptidyl Peptidase IV Inhibitor[3]
- Modality
- Small molecule[3]
- Highest Phase
- Approved[1]
- Company